By creator to www.biospace.com
Dr Korsgren to guide the analysis and growth of Hansa’s proprietary enzyme know-how platform because the Firm expands additionally into new therapeutic areas
LUND, Sweden, March 1, 2021 /PRNewswire/ — Hansa Biopharma, the pioneer in immunomodulatory enzyme know-how for uncommon IgG mediated ailments, at the moment proclaims the appointment of Magnus Korsgren, M.D., Ph.D. as Vice President and Head of Analysis and Growth.
Dr Korsgren will lead the efforts to advance Hansa Biopharma’s pipeline of drug candidates for uncommon immunologic ailments primarily based on the Firm’s proprietary IgG-cleaving enzyme know-how platform. Hansa’s lead asset, imlifidase, obtained conditional approval beneath the model title Idefirix®(imlifidase) within the European Union in August 2020 for desensitization remedy of extremely sensitized kidney transplant sufferers. Imlifidase can be at present being investigated at scientific stage for three extra indications: remedy of anti-glomerular basement membrane (anti-GBM) antibody illness, Guillain-Barre Syndrome (GBS) and antibody-mediated kidney transplant rejection (AMR) publish kidney transplantation. Hansa additionally has pre-clinical packages in gene remedy and most cancers and is growing a subsequent era of enzymes, NiceR.
“Magnus Korsgren’s in depth worldwide expertise in translational drugs and drug growth might be extremely invaluable for our continued efforts to construct a pipeline of drug candidates inside transplantation, autoimmune ailments and past”, mentioned Christian Kjellman, Chief Scientific Officer and Chief Working Officer.
Dr. Korsgren has an extended and in depth background from the life science trade and academia in each preclinical and scientific drug growth, with specific give attention to immunological mechanisms in inflammatory airway ailments, oncology and cardiovascular drugs. He brings greater than 15 years’ expertise from management positions in quite a lot of pharmaceutical and biotech firms, together with Ferring, AstraZeneca, BioInvent and Novartis.
Dr. Korsgren is board licensed in Medical Pharmacology and has revealed greater than 30 unique articles, critiques and e-book chapters.
“I’m very excited to affix the extremely revolutionary group at Hansa Biopharma”, mentioned Dr Korsgren. “It is a nice alternative for me to assist Hansa pioneer the subsequent wave of analysis into its enzyme cleaving know-how platform and to carry novel therapies from the laboratory to the sufferers with uncommon immunological ailments.”
Magnus Korsgren will take up his new function on 1st of April this yr.
The data was submitted for publication, via the contact particular person set out beneath, at 08:00 a.m. (CET) on March 1, 2021.
Contact data
Klaus Sindahl
Head of Investor Relations
Hansa Biopharma
M: +46 (0) 709-298 269
E: klaus.sindahl@hansabiopharma.com
Katja Margell
Head of Company Communications
Hansa Biopharma
M: +46 (0) 768-198 326
E: katja.margell@hansabiopharma.com
About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme know-how platform to develop immunomodulatory therapies for enabling transplantations and uncommon immunoglobulin G (IgG)-mediated autoimmune circumstances, gene remedy and most cancers.
The Firm’s lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to allow kidney transplantation in extremely sensitized sufferers and could also be additional developed to be used in different organ and tissue transplantation in addition to acute autoimmune indications.
Imlifidase has been granted conditional approval within the European Union for the desensitization remedy of extremely sensitized grownup kidney transplant sufferers with a optimistic crossmatch in opposition to an obtainable deceased donor.
Hansa’s analysis and growth program is advancing the Firm’s enzyme know-how to develop the subsequent era of IgG-cleaving enzymes with doubtlessly decrease immunogenicity, appropriate for repeat dosing in relapsing autoimmune ailments, gene remedy and oncology. Hansa Biopharma is predicated in Lund, Sweden and has operations in each Europe and the U.S.
Hansa Biopharma
Scheelevägen 22
SE- 223 63 Lund, Sweden
Telephone: +46 46 16 56 70
Nasdaq OMX Stockholm
This data was dropped at you by Cision http://news.cision.com
The next information can be found for obtain:
View unique content material:http://www.prnewswire.com/news-releases/hansa-biopharma-appoints-dr-magnus-korsgren-as-head-of-research–development-301237084.html
SOURCE Hansa Biopharma AB
Firm Codes: Bloomberg:HNSA@SS, ISIN:SE0002148817, Mexico:HNSA, OTC-PINK:HNSBF, RICS:HNSA.ST, Stockholm:HNSA
— to www.biospace.com
